retatrutide triple agonist glp-1 gip glucagon ly3437943 Eli Lilly announced pivotal Phase III results showing its triple-agonist drug delivered up to 22.6% weight loss in two separate trials, further cementing Lilly's position at the forefront of the obesity retatrutide triple agonist glp-1 gip
Pay in 4 interest-free payments of $6.88 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25


























